Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

The addition of blinatumomab to consolidation chemotherapy in adults with B-cell precursor acute lymphoblastic leukemia who had minimal residual disease–negative status after treatment improved overall and relapse-free survival.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-07, Vol.391 (4), p.320-333
Hauptverfasser:	Litzow, Mark R., Sun, Zhuoxin, Mattison, Ryan J., Paietta, Elisabeth M., Roberts, Kathryn G., Zhang, Yanming, Racevskis, Janis, Lazarus, Hillard M., Rowe, Jacob M., Arber, Daniel A., Wieduwilt, Matthew J., Liedtke, Michaela, Bergeron, Julie, Wood, Brent L., Zhao, Yaqi, Wu, Gang, Chang, Ti-Cheng, Zhang, Wenchao, Pratz, Keith W., Dinner, Shira N., Frey, Noelle, Gore, Steven D., Bhatnagar, Bhavana, Atallah, Ehab L., Uy, Geoffrey L., Jeyakumar, Deepa, Lin, Tara L., Willman, Cheryl L., DeAngelo, Daniel J., Patel, Shejal B., Elliott, Michelle A., Advani, Anjali S., Tzachanis, Dimitrios, Vachhani, Pankit, Bhave, Rupali R., Sharon, Elad, Little, Richard F., Erba, Harry P., Stone, Richard M., Luger, Selina M., Mullighan, Charles G., Tallman, Martin S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia Adult Age Aged Antibodies, Bispecific - administration & dosage Antibodies, Bispecific - adverse effects Antibodies, Bispecific - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone marrow Cancer therapies Chemotherapy Clinical trials Consolidation Chemotherapy Data collection Disease-Free Survival FDA approval Female Flow cytometry Hematology Humans Induction Chemotherapy Induction therapy Kaplan-Meier Estimate Leukemia Lymphatic leukemia Lymphocytes B Lymphocytes T Lymphoma Male Medical prognosis Middle Aged Monoclonal antibodies Neoplasm, Residual Oncology Pediatrics Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology Recurrence Remission Remission (Medicine) Remission Induction Survival Analysis Targeted cancer therapy Transplants & implants Treatments in Oncology Young adults
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The addition of blinatumomab to consolidation chemotherapy in adults with B-cell precursor acute lymphoblastic leukemia who had minimal residual disease–negative status after treatment improved overall and relapse-free survival.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2312948